Equasens (FR:EQS)
:EQS
Want to see FR:EQS full AI Analyst Report?
Top Page
Equasens
(EQS)
Select Model
Select Model
Rating:79Outperform
Price Target:
€42.00
▲(0.24% Upside)
Action:Reiterated
Date:04/17/26
The score is driven primarily by strong underlying financial quality and an attractive valuation (low P/E with a solid dividend yield). Technicals are supportive but somewhat stretched and still below the 200-day average, which slightly offsets the overall rating.
Positive Factors
Durable profitability / ROE
Equasens reports historically strong ROE (≈15–25%) with 2025 ROE ~14.9% and solid operating margins (~20%). Sustained profitability provides durable internal funding for R&D, supports dividend capacity and underpins competitive resilience in its software niche over multiple quarters.
Negative Factors
Margin drift & data gaps
Margins have trended down versus the 2021–2023 period and the 2025 gross profit line is missing in reported data. Persistent margin erosion and reduced transparency weaken visibility into cost structure and operating leverage, complicating durable earnings forecasts.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable profitability / ROE
Equasens reports historically strong ROE (≈15–25%) with 2025 ROE ~14.9% and solid operating margins (~20%). Sustained profitability provides durable internal funding for R&D, supports dividend capacity and underpins competitive resilience in its software niche over multiple quarters.
Read all positive factors
Equasens (EQS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€564.77M
Dividend Yield2.85%
Average Volume (3M)10.91K
Price to Earnings (P/E)17.4
Beta (1Y)0.71
Revenue Growth9.12%
EPS Growth8.55%
CountryFR
Employees1,271
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)2.59
Shares Outstanding15,174,125
10 Day Avg. Volume9,833
30 Day Avg. Volume10,915
Financial Highlights & Ratios
PEG Ratio2.33
Price to Book (P/B)2.60
Price to Sales (P/S)2.89
P/FCF Ratio14.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.04
Revenue Forecast (FY)€260.90M
Equasens Business Overview & Revenue Model
Company Description
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, ...
How the Company Makes Money
Equasens makes money mainly by selling and supporting healthcare IT solutions, with revenues typically coming from (i) software licensing and/or subscription fees for its applications used by pharmacies and related healthcare customers, (ii) maint...
Equasens Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
80
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 236.50M | 216.80M | 219.79M | 214.07M | 193.07M |
| Gross Profit | 162.58M | 47.13M | 69.88M | 145.52M | 133.82M |
| EBITDA | 70.96M | 62.99M | 71.30M | 67.36M | 63.77M |
| Net Income | 39.30M | 36.20M | 47.05M | 46.38M | 39.12M |
Balance Sheet | |||||
| Total Assets | 439.00M | 398.01M | 394.05M | 350.81M | 329.95M |
| Cash, Cash Equivalents and Short-Term Investments | 87.10M | 40.16M | 54.69M | 68.01M | 64.79M |
| Total Debt | 53.80M | 48.45M | 69.27M | 66.52M | 84.06M |
| Total Liabilities | 176.00M | 157.32M | 166.42M | 154.01M | 164.72M |
| Stockholders Equity | 263.00M | 231.51M | 219.28M | 189.78M | 159.00M |
Cash Flow | |||||
| Free Cash Flow | 47.10M | 35.91M | 43.17M | 46.75M | 37.09M |
| Operating Cash Flow | 59.20M | 47.55M | 61.59M | 56.98M | 47.52M |
| Investing Cash Flow | -12.10M | -13.90M | -50.53M | -20.82M | -36.19M |
| Financing Cash Flow | -48.50M | -36.20M | -16.09M | -39.88M | -9.80M |
Equasens Technical Analysis
Neutral
41.90
Price Trends
37.70
Negative
38.34
Negative
40.72
Negative
Market Momentum
-0.37
Negative
49.60
Neutral
69.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Neutral. The current price of 41.9 is above the 20-day moving average (MA) of 37.45, above the 50-day MA of 37.70, and above the 200-day MA of 40.72, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 69.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:EQS.
Equasens Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | €564.77M | 17.37 | 16.40% | 2.85% | 9.12% | 8.55% | |
60 Neutral | €158.26M | 16.89 | -5.44% | ― | -0.81% | ― | |
57 Neutral | €222.12M | 25.01 | 1.32% | ― | 9.08% | 21.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | €202.80M | -1.75 | 59.08% | ― | 1.79% | 15.89% |
* General Sector Average
FR:EQS
Equasens
37.60
-12.20
-24.49%
FR:ALCGM
Cegedim
11.54
0.14
1.23%
FR:ALERS
Eurobio-Scientific SA
22.20
-3.25
-12.77%
FR:ALMDT
Median Technologies
5.39
3.19
145.00%
FR:ALBIO
Biosynex SA
1.04
-0.48
-31.46%
FR:ABLD
ABL Diagnostics SA
3.50
-1.90
-35.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.